Gemini Bioproducts LLC, which is backed by BelHealth Investment Partners LLC, has named John Roderick as chief operating officer and Scott Kantor as chief financial officer. Recently, Roderick was director of validation for Gilead Sciences Inc while Kantor previously spent 4 years at a BelHealth portfolio company, where he held CFO and COO roles overseeing finance, accounting and operations. Gemini is a maker of biological products and chemical reagents for the cell culture community.
New York, New York and West Sacramento, CA – October 8, 2018 – Gemini Bioproducts, LLC (“Gemini” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, announced the appointment of two new senior executive members.
Gemini named John “Jay” Roderick as Chief Operating Officer (“COO”). Mr. Roderick has over 12 years of experience across leadership roles in engineering and manufacturing at large biopharma companies including Shire PLC (NASDAQ: SHPG), Lonza Group AG (SWX: LONN), and Novartis AG (NYSE: NVS). Most recently, Mr. Roderick served as a Director of Validation for Gilead Sciences, Inc. (NASDAQ: GILD). Across his career, Mr. Roderick has had responsibility across diverse operational functions including site buildout and expansion, quality, supply chain and logistics, procurement, packaging, and safety and environmental health. Prior to biopharma, Mr. Roderick proudly served as a submarine nuclear engineer for the US Navy for 7 years.
The Company also named Scott Kantor as Chief Financial Officer (“CFO”). Mr. Kantor has over 34 years of experience in progressive financial and accounting roles across public and private companies in many diverse industries including healthcare. Mr. Kantor previously spent 4 years at a BelHealth portfolio company, where he held CFO and COO roles overseeing finance, accounting and operations. Earlier in his career, Mr. Kantor had financial responsibility at Costar Corporation, now part of Corning Inc. (NYSE: GLW), which sold consumable products and equipment to similar endpoints as Gemini. Mr. Kantor began his career at Deloitte & Touche.
Dale Gordon, CEO of Gemini, stated “I am delighted to welcome Jay and Scott to the Gemini executive leadership team. Jay’s deep operational experience at established biopharmaceutical companies will be instrumental to Gemini’s quality focus, while Scott’s track record as a former CFO and COO with BelHealth will bolster Gemini’s business and financial strategy. Alongside Jay and Scott, I look forward to growing Gemini as we continue to provide best-in-class service and quality products to our customers across academic research communities and the biotechnology industry.”
About Gemini Bio-Products
Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from a 14,000 square foot manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.
For further information, please visit: BelHealth Investment Partners: www.belhealth.com